Research ArticleArticle
Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark
Vera Ehrenstein, Søren L. Andersen, Ibrahim Qazi, Neil Sankar, Alma B. Pedersen, Robert Sikorski and John F. Acquavella
The Journal of Rheumatology August 2017, jrheum.160816; DOI: https://doi.org/10.3899/jrheum.160816
Vera Ehrenstein
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Søren L. Andersen
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Ibrahim Qazi
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Neil Sankar
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Alma B. Pedersen
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Robert Sikorski
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
John F. Acquavella
From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA. This study was partially funded by a research grant from Five Prime Therapeutics Inc., issued to and administered by Aarhus University Hospital. V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital. Address correspondence and to Dr. V. Ehrenstein, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark. E-mail: ve@clin.au.dk. Accepted for publication May 18, 2017.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark
Vera Ehrenstein, Søren L. Andersen, Ibrahim Qazi, Neil Sankar, Alma B. Pedersen, Robert Sikorski, John F. Acquavella
The Journal of Rheumatology Aug 2017, jrheum.160816; DOI: 10.3899/jrheum.160816
Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark
Vera Ehrenstein, Søren L. Andersen, Ibrahim Qazi, Neil Sankar, Alma B. Pedersen, Robert Sikorski, John F. Acquavella
The Journal of Rheumatology Aug 2017, jrheum.160816; DOI: 10.3899/jrheum.160816